Ghassan K. Abou‐Alfa

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +11

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Lawrence H. Schwartz, Sergio Ricci et al. · Journal of Clinical Oncology · 2006 · 1.2K citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Ghassan K. Abou‐Alfa, Teresa Macarulla, Milind Javle et al. · The Lancet Oncology · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +8